tirzepatide court UPDATE [March 7, 2025]: OFA takes case to appeals as legal battle evolves FDA's tirzepatide decision creates uncertainty court ruling on tirzepatide case – FDA says the tirzepatide weight-loss

This serious adverse effect requires prompt recognition and discontinuation of semaglutide

Although vaccine manufacturing capacity exists for the classical platforms, using the existing infrastructure would potentially go at the expense of regular vaccine production

While compounded GLP-1 injections may appear more affordable, they often lack standardized testing and consistency

How Merit compares to the two alternatives most research buyers consider for Tirzepatide

In 2021, semaglutides weight-loss brand Wegovy (weekly injectable) was approved for obesity, followed by tirzepatide (Mounjaro) for diabetes (2022) and Zepbound (tirzepatide for obesity) in late 2023